statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug...

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284

Lantern Pharma Inc., (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform...

Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates

Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates PR Newswire VANCOUVER, BC...

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform...

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 A Potent Inhibitor of Cancer Metabolism

Lantern Pharma Inc. (NASDAQ: LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French...

Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET

Lantern Pharma Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth

Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth PR...

Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028

PALM BEACH, Fla., March 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The use of Artificial Intelligence (AI) in medical diagnosis is taking broad strides in recent years and is...

Short Interest in Lantern Pharma Inc. (NASDAQ:LTRN) Increases By 14.1%

Lantern Pharma Inc. (NASDAQ:LTRN  Get Free Report) saw a significant growth in short interest in the month of February. As of February 29th, there was short interest totalling 68,000 shares...

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.

Volume	22,814.00
52-Wk High	$11.99
52-Wk Low	$2.38

LTRN Lantern Pharma Inc

About

Feed

News

Sentiment

Earnings

Fundamentals